CRBP

Corbus Pharmaceuticals Holdings, Inc.

25.62 USD
-0.13 (-0.50%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Corbus Pharmaceuticals Holdings, Inc. stock is up 203.55% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 9 February’s closed higher than January. 100% of analysts rate it a buy.

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus. CRB-601, an anti-integrin monoclonal antibody (mAb) that inhibits the activation of transforming growth factor ß (TGFß)